CMI 947

Drug Profile

CMI 947

Latest Information Update: 24 Aug 2000

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Antiallergics
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 24 Aug 2000 Discontinued-Preclinical for Asthma in USA (Unknown route)
  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
  • 24 Feb 1999 CytoMed has been wholly acquired by LeukoSite
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top